Dynamics of interferon-β modulated mRNA biomarkers in multiple sclerosis patients with anti-interferon-β neutralizing antibodies

Journal of Neuroimmunology

Volumn 176, Issue 1-2, 2006, Pages 125-133

  Santos, Roseane ^a   Weinstock Guttman, Bianca ^b   Tamaño Blanco, Miriam ^a   Badgett, Darlene ^a   Zivadinov, Robert ^b   Justinger, Theresa ^b   Munschauer III, Frederick ^b   Ramanathan, Murali ^a,b  

^a UNIVERSITY AT BUFFALO   (United States)

^b BUFFALO GENERAL HOSPITAL   (United States)

Author keywords

Antibodies; Gene expression; Interferons; Multiple sclerosis; Pharmacodynamics

Indexed keywords

BETA 2 MICROGLOBULIN; BETA1A INTERFERON; BIOLOGICAL MARKER; COMPLEMENTARY DNA; INTERFERON ANTIBODY; INTERFERON BETA NEUTRALIZING ANTIBODY; MESSENGER RNA; MYXOVIRUS RESISTANCE PROTEIN; MYXOVIRUS RESISTANCE PROTEIN A; MYXOVIRUS RESISTANCE PROTEIN B; RNA; STAT1 PROTEIN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG;

ADULT; ANTIGEN BINDING; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; IMMUNOGENICITY; IMMUNOMODULATION; MALE; MEASUREMENT; MULTIPLE SCLEROSIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PHARMACODYNAMICS; PRIORITY JOURNAL; QUANTITATIVE ASSAY; REAL TIME POLYMERASE CHAIN REACTION;

ADULT; ANTIBODIES; APOPTOSIS REGULATORY PROTEINS; BETA 2-MICROGLOBULIN; BIOLOGICAL MARKERS; FEMALE; GENE EXPRESSION; GTP-BINDING PROTEINS; HUMANS; INTERFERON-BETA; MALE; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; MULTIPLE SCLEROSIS; RNA, MESSENGER; STAT1 TRANSCRIPTION FACTOR; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33746078848     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2006.03.019     Document Type: Article

References (33)

1. Alves A.V., de Azevedo A.P., Perin C., Ramos G.Z., Brandao A.B., de Mattos A.A., and de Almeida P.R. Interferon-alpha and ribavirin therapy on chronic hepatitis C virus infection: the experience of Rio Grande do Sul State Health Department, Brazil. Arq. Gastroenterol. 40 (2003) 227-232
2. Arbour N., Rastikerdar E., McCrea E., Lapierre Y., Dorr J., Bar-Or A., and Antel J.P. Upregulation of TRAIL expression on human T lymphocytes by interferon beta and glatiramer acetate. Mult. Scler. 11 (2005) 652-657
3. Bertolotto A., Malucchi S., Milano E., Castello A., Capobianco M., and Mutani R. Interferon beta neutralizing antibodies in multiple sclerosis: neutralizing activity and cross-reactivity with three different preparations. Immunopharmacology 48 (2000) 95-100
4. Bertolotto A., Gilli F., Sala A., Audano L., Castello A., Magliola U., Melis F., and Giordana M.T. Evaluation of bioavailability of three types of IFNbeta in multiple sclerosis patients by a new quantitative-competitive-PCR method for MxA quantification. J. Immunol. Methods 256 (2001) 141-152
5. Bertolotto A., Gilli F., Sala A., Capobianco M., Malucchi S., Milano E., Melis F., Marnetto F., Lindberg R.L., Bottero R., Di Sapio A., and Giordana M.T. Persistent neutralizing antibodies abolish the interferon beta bioavailability in MS patients. Neurology 60 (2003) 634-639
6. Buchwalder P.A., Buclin T., Trinchard I., Munafo A., and Biollaz J. Pharmacokinetics and pharmacodynamics of IFN-beta 1a in healthy volunteers. J. Interferon Cytokine Res. 20 (2000) 857-866
7. Bustin S.A. Absolute quantification of mRNA using real-time reverse transcription polymerase chain reaction assays. J. Mol. Endocrinol. 25 (2000) 169-193
8. Der S.D., Zhou A., Williams B.R., and Silverman R.H. Identification of genes differentially regulated by interferon alpha, beta, or gamma using oligonucleotide arrays. Proc. Natl. Acad. Sci. U. S. A. 95 (1998) 15623-15628
9. Feng X., Petraglia A.L., Chen M., Byskosh P.V., Boos M.D., and Reder A.T. Low expression of interferon-stimulated genes in active multiple sclerosis is linked to subnormal phosphorylation of STAT1. J. Neuroimmunol. 129 (2002) 205-215
10. Fierlbeck G., Ulmer A., Schreiner T., Stroebel W., Schiebel U., and Brzoska J. Pharmacodynamics of recombinant IFN-beta during long-term treatment of malignant melanoma. J. Interferon Cytokine Res. 16 (1996) 777-781
11. Francis G.S., Rice G.P., and Alsop J.C. Interferon beta-1a in MS: results following development of neutralizing antibodies in PRISMS. Neurology 65 (2005) 48-55
12. Gilli F., Marnetto F., Caldano M., Sala A., Malucchi S., Capobianco M., and Bertolotto A. Biological markers of interferon-therapy: comparison among interferon-stimulated genes MxA, TRAIL and XAF-1. Mult. Scler. 12 (2006) 47-57
13. Hargrove J.L., and Schmidt F.H. The role of mRNA and protein stability in gene expression. FASEB J. 3 (1989) 2360-2370
14. Hartrich L., Weinstock-Guttman B., Hall D., Badgett D., Baier M., Patrick K., Feichter J., Hong J., and Ramanathan M. Dynamics of immune cell trafficking in interferon-beta treated multiple sclerosis patients. J. Neuroimmunol. 139 (2003) 84-92
15. Jacobs L.D., Cookfair D.L., Rudick R.A., Herndon R.M., Richert J.R., Salazar A.M., Fischer J.S., Goodkin D.E., Granger C.V., Simon J.H., Alam J.J., Bartoszak D.M., Bourdette D.N., Braiman J., Brownscheidle C.M., Coats M.E., Cohan S.I., Dougherty D.S., Kinkel R.P., Mass M.K., Munschauer F.E.r., Priore R.I., Pullicino P.M., Scherokman B.J., Whitham R.H., et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann. Neurol. 39 (1996) 285-294
16. Jouet P., Roudot-Thoraval F., Dhumeaux D., and Metreau J.M. Comparative efficacy of interferon alfa in cirrhotic and noncirrhotic patients with non-A, non-B, C hepatitis. Le Groupe Francais pour l'Etude du Traitement des Hepatites Chroniques NANB/C. Gastroenterology 106 (1994) 686-690
17. McHutchison J.G., and Fried M.W. Current therapy for hepatitis C: pegylated interferon and ribavirin. Clin. Liver Dis. 7 (2003) 149-161
18. Munschauer F.E., Herndon R.M., Sandrock A.W., Tsao E., B. J.E., and Stubbendick A. A study of the effect of gender on interferon beta-1a (Avonex 30 mcg) treatment in patients with multiple sclerosis. Mult. Scler. 11 (2005) S78
19. Oh S.K., Luhowskyj S., Witt P., Ritch P., Reitsma D., Towbin H., Horisberger M., von Wussow P., and Bluestein B. Quantitation of interferon-induced Mx protein in whole blood lysates by an immunochemiluminescent assay: elimination of protease activity of cell lysates in toto. J. Immunol. Methods 176 (1994) 79-91
20. Pachner A.R. An improved ELISA for screening for neutralizing anti-IFN-beta antibodies in MS patients. Neurology 61 (2003) 1444-1446
21. Pachner A.R., Bertolotto A., and Deisenhammer F. Measurement of MxA mRNA or protein as a biomarker of IFNbeta bioactivity: detection of antibody-mediated decreased bioactivity (ADB). Neurology 61 (2003) S24-S26
22. Pachner A.R., Dail D., Pak E., and Narayan K. The importance of measuring IFNbeta bioactivity: monitoring in MS patients and the effect of anti-IFNbeta antibodies. J. Neuroimmunol. 166 (2005) 180-188
23. Panitch H., Goodin D.S., Francis G., Chang P., Coyle P.K., O'Connor P., Monaghan E., Li D., and Weinshenker B. Randomized, comparative study of interferon beta-1a treatment regimens in MS: The EVIDENCE Trial. Neurology 59 (2002) 1496-1506
24. Perini P., Facchinetti A., Bulian P., Massaro A.R., Pascalis D.D., Bertolotto A., Biasi G., and Gallo P. Interferon-beta (INF-beta) antibodies in interferon-beta1a- and interferon-beta1b-treated multiple sclerosis patients. Prevalence, kinetics, cross-reactivity, and factors enhancing interferon-beta immunogenicity in vivo. Eur. Cytokine Netw. 12 (2001) 56-61
25. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet 352 (1998) 1498-1504
26. Rudick R.A., Simonian N.A., Alam J.A., Campion M., Scaramucci J.O., Jones W., Coats M.E., Goodkin D.E., Weinstock-Guttman B., Herndon R.M., Mass M.K., Richert J.R., Salazar A.M., Munschauer III F.E., Cookfair D.L., Simon J.H., and Jacobs L.D. Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis. Multiple Sclerosis Collaborative Research Group (MSCRG). Neurology 50 (1998) 1266-1272
27. Salmon P., Le Cotonnec J.Y., Galazka A., Abdul-Ahad A., and Darragh A. Pharmacokinetics and pharmacodynamics of recombinant human interferon-beta in healthy male volunteers. J. Interferon Cytokine Res. 16 (1996) 759-764
28. Stark G.R., Kerr I.M., Williams B.R., Silverman R.H., and Schreiber R.D. How cells respond to interferons. Ann. Rev. Biochem. 67 (1998) 227-264
29. Sturzebecher S., Maibauer R., Heuner A., Beckmann K., and Aufdembrinke B. Pharmacodynamic comparison of single doses of IFN-beta1a and IFN-beta1b in healthy volunteers. J. Interferon Cytokine Res. 19 (1999) 1257-1264
30. The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis: I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 43 (1993) 655-661
31. The IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group. Neutralizing antibodies during treatment of multiple sclerosis with interferon beta-1b: experience during the first three years. Neurology 47 (1996) 889-894
32. Wandinger K.P., Lunemann J.D., Wengert O., Bellmann-Strobl J., Aktas O., Weber A., Grundstrom E., Ehrlich S., Wernecke K.D., Volk H.D., and Zipp F. TNF-related apoptosis inducing ligand (TRAIL) as a potential response marker for interferon-beta treatment in multiple sclerosis. Lancet 361 (2003) 2036-2043
33. Weinstock-Guttman B., Badgett D., Patrick K., Hartrich L., Santos R., Hall D., Baier M., Feichter J., and Ramanathan M. Genomic effects of IFN-beta in multiple sclerosis patients. J. Immunol. 171 (2003) 2694-2702